# TP05 for the Treatment of Mild to Moderate Active Ulcerative Colitis (UC)

> **NCT01903252** · PHASE3 · COMPLETED · sponsor: **Tillotts Pharma AG** · enrollment: 817 (actual)

## Conditions studied

- Acute Ulcerative Colitis

## Interventions

- **DRUG:** TP05
- **DRUG:** Asacol 400 mg

## Key facts

- **NCT ID:** NCT01903252
- **Lead sponsor:** Tillotts Pharma AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2016-05
- **Final completion:** 2016-11
- **Target enrollment:** 817 (ACTUAL)
- **Last updated:** 2018-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01903252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01903252, "TP05 for the Treatment of Mild to Moderate Active Ulcerative Colitis (UC)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01903252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*